Lipoprotein disorders causes

Jump to navigation Jump to search

Lipoprotein Disorders Microchapters

Patient Information

Overview

Causes

Classification

Hyperlipoproteinemia
Hypolipoproteinemia

Treatment

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hardik Patel, M.D.

Overview

Hyperlipidemias are caused by primary and secondary causes. Primary hyperlipidemia is usually due to genetic causes (such as a mutation in a receptor protein) such as chylomicronemia, hypercholesterolemia, dysbetalipoproteinemia, hypertriglyceridemia, mixed hyperlipoproteinemia, and combined hyperlipoproteinemia, while secondary hyperlipidemia arises due to other underlying causes such as diabetes. Lipid and lipoprotein abnormalities are common in the general population, and are regarded as a modifiable risk factor for cardiovascular disease due to their influence on atherosclerosis. In addition, some forms may predispose to acute pancreatitis.

Causes

Familial (Primary) Hyperlipidemia

Hyperlipoproteinemia Type I

Type I hyperlipoproteinemia exists in several forms:

Type I hyperlipoproteinemia usually presents in childhood with eruptive xanthomata and abdominal colic. Complications include retinal vein occlusion, acute pancreatitis, steatosis and organomegaly, and lipemia retinalis.

Hyperlipoproteinemia Type II

Hyperlipoproteinemia type II, by far the most common form, is further classified into type IIa and type IIb, depending mainly on whether there is elevation in the triglyceride level in addition to LDL cholesterol.

Type IIa

This may be sporadic (due to dietary factors), polygenic, or truly familial as a result of a mutation either in the LDL receptor gene on chromosome 19 (0.2% of the population) or the ApoB gene (0.2%). The familial form is characterized by tendon xanthoma, xanthelasma and premature cardiovascular disease. The incidence of this disease is about 200 in 100,000 for heterozygotes, and 0.1 in 100,000 for homozygotes.

Type IIb

The high VLDL levels are due to overproduction of substrates, including triglycerides, acetyl CoA, and an increase in B-100 synthesis. They may also be caused by the decreased clearance of LDL. Prevalence in the population is 10%.

Hyperlipoproteinemia Type III

This form is due to high chylomicrons and IDL (intermediate density lipoprotein). Also known as broad beta disease or dysbetalipoproteinemia, the most common cause for this form is the presence of ApoE E2/E2 genotype. It is due to cholesterol-rich VLDL (β-VLDL). Its prevalence has been estimated to be approximately 1 in 10,000.

Hyperlipoproteinemia Type IV

Familial hypertriglyceridemia is an autosomal dominant condition occurring in approximately 1% of the population.

Hyperlipoproteinemia Type V

  • Very similar to type I, but with high VLDL in addition to chylomicrons
  • Associated with glucose intolerance and hyperuricemia

Familial Lecithin-cholesterol Acyltransferase (LCAT) Deficiency[5]

  • Caused by mutations of the LCAT gene located on chromosome 16q22, which is passed on in an autosomal recessive fashion
  • Associated with corneal opacities, hemolytic anaemia, and proteinuria

Secondary Hyperlipidemia

Secondary to some underlying "non-lipid" etiology:

Causes

By Organ System

Cardiovascular Alagille syndrome
Chemical / poisoning No underlying causes
Dermatologic No underlying causes
Drug Side Effect Amprenavir, atazanavir sulfate, atypical antipsychotics, bendrofluazide, beta blockers, bexarotene, chenodeoxycholic acid, chlorthalidone, clofibrate, colesevelam hydrochloride, colestyramine, combined oral contraceptive pill, cyclopenthiazide, danazol, desvenlafaxine, doxazosin, ethanol, etretinate, fosamprenavir, gestrinone, hydrochlorothiazide, interferon alpha, isotretinoin, linagliptin, lopinavir, mitotane, nelfinavir, prazosin, progestagens, propofol, protease inhibitors, ritonavir, rosiglitazone, saquinavir, sirolimus, temsirolimus, testosterone, thiazide diuretics, tipranavir, tocilizumab, tofacitinib, torcetrapib
Ear Nose Throat No underlying causes
Endocrine Cushing syndrome, diabetes mellitus type 2, hypothyroidism, metabolic syndrome, hypopituitarism
Environmental No underlying causes
Gastroenterologic Cholestatic jaundice, intrahepatic cholestasis, malignant hepatopathy, pancreatitis, Alagille syndrome
Genetic Alagille syndrome, Alstrom syndrome, analbuminaemia, apolipoprotein C-II deficiency, apoprotein E deficiency, Berardinelli-Seip congenital lipodystrophy, carnitine palmitoyltransferase 1 deficiency, chromosome 15q deletion, familial alphalipoprotein deficiency, familial defective apolipoprotein B-100, familial hypertriglyceridaemia, familial isolated vitamin E deficiency, familial mixed hyperlipidemia, fructose-1, 6-diphosphatase deficiency, glycogen storage diseases, lecithin cholesterol acyltransferase deficiency, lipoprotein lipase deficiency, Niemann-Pick disease , primary hyperlipoproteinemia, Smith-Lemli-Opitz syndrome, Werner syndrome
Hematologic No underlying causes
Iatrogenic Parenteral nutrition
Infectious Disease Sepsis
Musculoskeletal / Ortho Smith-Lemli-Opitz syndrome
Neurologic Growth hormone secreting pituitary adenoma
Nutritional / Metabolic Dysglobulinemia, LDL receptor deficiency, omega-3 polyunsaturated fatty acids, selenium deficiency, vitamin E deficiency, Smith-Lemli-Opitz syndrome, apolipoprotein C-II deficiency, apoprotein E deficiency, carnitine palmitoyltransferase 1 deficiency, familial isolated vitamin E deficiency, fructose-1, 6-diphosphatase deficiency, glycogen storage diseases, lecithin cholesterol acyltransferase deficiency, lipoprotein lipase deficiency, Niemann-Pick disease , primary hyperlipoproteinemia
Obstetric/Gynecologic Pregnancy
Oncologic Growth hormone secreting pituitary adenoma
Opthalmologic No underlying causes
Overdose / Toxicity Amprenavir, atazanavir sulfate, atypical antipsychotics, bendrofluazide, beta blockers, bexarotene, chenodeoxycholic acid, chlorthalidone, clofibrate, colesevelam hydrochloride, colestyramine, combined oral contraceptive pill, cyclopenthiazide, danazol, desvenlafaxine, doxazosin, ethanol, etretinate, fosamprenavir, gestrinone, hydrochlorothiazide, interferon alpha, isotretinoin, linagliptin, lopinavir, mitotane, nelfinavir, prazosin, progestagens, propofol, protease inhibitors, ritonavir, rosiglitazone, saquinavir, sirolimus, temsirolimus, testosterone, thiazide diuretics, tipranavir, tocilizumab, tofacitinib, torcetrapib
Psychiatric Anorexia nervosa
Pulmonary No underlying causes
Renal / Electrolyte Chronic renal failure, nephrotic syndrome, Alagille syndrome
Rheum / Immune / Allergy Macrophage activation syndrome
Sexual No underlying causes
Trauma No underlying causes
Urologic No underlying causes
Dental No underlying causes
Miscellaneous Alcohol abuse, benign symmetrical lipomatosis, exercise, high fat diet, obesity, positive family history, sedentary lifestyle , stress, tobacco smoking

Causes

In Alphabetical Order


References

  1. OMIM entry 207750 last updated 02/10/2009
  2. PMID 227429 (PMID 227429)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  3. James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0.
  4. OMIM entry 118830 updated 03/18/2004
  5. McIntyre N (1988). "Familial LCAT deficiency and fish-eye disease". J Inherit Metab Dis. 11 Suppl 1: 45–56. PMID 3141686.
  6. Rosenson RS, Baker AL, Chow MJ, Hay RV (1990). "Hyperviscosity syndrome in a hypercholesterolemic patient with primary biliary cirrhosis". Gastroenterology. 98 (5 Pt 1): 1351–7. PMID 2323525.
  7. Zavaroni I, Dall'Aglio E, Alpi O, Bruschi F, Bonora E, Pezzarossa A; et al. (1985). "Evidence for an independent relationship between plasma insulin and concentration of high density lipoprotein cholesterol and triglyceride". Atherosclerosis. 55 (3): 259–66. PMID 3893447.
  8. O'Brien T, Dinneen SF, O'Brien PC, Palumbo PJ (1993). "Hyperlipidemia in patients with primary and secondary hypothyroidism". Mayo Clin Proc. 68 (9): 860–6. PMID 8371604.
  9. Hubert HB, Feinleib M, McNamara PM, Castelli WP (1983). "Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study". Circulation. 67 (5): 968–77. PMID 6219830.
  10. Facchini FS, Hollenbeck CB, Jeppesen J, Chen YD, Reaven GM (1992). "Insulin resistance and cigarette smoking". Lancet. 339 (8802): 1128–30. PMID 1349365.
  11. Henderson DC (2001). "Clozapine: diabetes mellitus, weight gain, and lipid abnormalities". J Clin Psychiatry. 62 Suppl 23: 39–44. PMID 11603884.
  12. Osser DN, Najarian DM, Dufresne RL (1999). "Olanzapine increases weight and serum triglyceride levels". J Clin Psychiatry. 60 (11): 767–70. PMID 10584766.


Template:WikiDoc Sources